Genmab — Marts 2011
-
Det er ikke vores fejl, det er genmabs ansvar at steppe op nu til IR udfordringen
-
på sammenlignelige nøgletal er det ikke det dyreste biotek selskab hverken i EU eller DK
-
så må de jo igang med at gøre noget for de små investorer
-
Jeg rapporterer fra webcast kl 15.00
-
her på kanalen
-
tror der er nogen der bliver stoppet ud af den nu.
-
det tror jeg ikke
-
-
ja det er ret utroligt
-
vi venter stadig....med kammermusik in starch contrast
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind